Uma Siangphoe1, Kellie J Archer2, Christopher Nguyen3, Kwan R Lee4. 1. Janssen Research and Development, Johnson and Johnson, Raritan, New Jersey. 2. Division of Biostatistics, College of Public Health, The Ohio State University. 3. Department of Psychiatry and Behavioral Health, Wexner Medical Center, The Ohio State University, Columbus, Ohio. 4. Janssen Research and Development, Johnson and Johnson, Spring House, Philadelphia, Pennsylvania, USA.
Abstract
OBJECTIVE: The aim of this study was to evaluate associations of antiretroviral therapy (ART) and comorbidities with neurocognitive impairments (NCIs) in ART-naive HIV-1-infected patients in clinical practice. DESIGN: A retrospective study was conducted in ART-naive patients with HIV-1 diagnosis between January 2009 and December 2013 in the United States. METHODS: The primary outcome was any NCI that included HIV-associated neurocognitive disorders (HAND), Alzheimer's disease, Parkinson's disease, multiple sclerosis, and other dementias. RESULTS: A total of 47 862 patients met eligibility criteria (30 828 antiretroviral-treated and 17 034 antiretroviral-untreated). The median age was 45 years [interquartile range (IQR) 35--52] with 31% of patients aged at least 50 years. Seventy-five percent were men. Overall, ART was associated with reduced risks of any NCI (hazard ratio 0.41, 95% CI: 0.37--0.45), HAND (hazard ratio 0.57, 95% CI: 0.48--0.69), Alzheimer's disease (hazard ratio 0.36, 95% CI: 0.24--0.54), Parkinson's disease (hazard ratio 0.36, 95% CI: 0.25--0.51), multiple sclerosis (hazard ratio 0.26, 95% CI: 0.18--0.37), and other dementias (hazard ratio 0.50, 95% CI: 0.45--0.55). Meanwhile, the risk of any NCI was significantly increased in patients with various comorbidities including cardiac arrhythmia, paralysis, other neurological disorders, complicated diabetes, hypothyroidism, renal failure, lymphoma, rheumatoid arthritis, weight loss, and depression as compared with patients without those comorbidities. CONCLUSION: ART may reduce the risk of NCIs in HIV-infected patients in general. Further research to investigate NCIs on specific antiretroviral regimens and comorbidities may provide insights regarding the long-term clinical care of these patients.
OBJECTIVE: The aim of this study was to evaluate associations of antiretroviral therapy (ART) and comorbidities with neurocognitive impairments (NCIs) in ART-naive HIV-1-infected patients in clinical practice. DESIGN: A retrospective study was conducted in ART-naive patients with HIV-1 diagnosis between January 2009 and December 2013 in the United States. METHODS: The primary outcome was any NCI that included HIV-associated neurocognitive disorders (HAND), Alzheimer's disease, Parkinson's disease, multiple sclerosis, and other dementias. RESULTS: A total of 47 862 patients met eligibility criteria (30 828 antiretroviral-treated and 17 034 antiretroviral-untreated). The median age was 45 years [interquartile range (IQR) 35--52] with 31% of patients aged at least 50 years. Seventy-five percent were men. Overall, ART was associated with reduced risks of any NCI (hazard ratio 0.41, 95% CI: 0.37--0.45), HAND (hazard ratio 0.57, 95% CI: 0.48--0.69), Alzheimer's disease (hazard ratio 0.36, 95% CI: 0.24--0.54), Parkinson's disease (hazard ratio 0.36, 95% CI: 0.25--0.51), multiple sclerosis (hazard ratio 0.26, 95% CI: 0.18--0.37), and other dementias (hazard ratio 0.50, 95% CI: 0.45--0.55). Meanwhile, the risk of any NCI was significantly increased in patients with various comorbidities including cardiac arrhythmia, paralysis, other neurological disorders, complicated diabetes, hypothyroidism, renal failure, lymphoma, rheumatoid arthritis, weight loss, and depression as compared with patients without those comorbidities. CONCLUSION: ART may reduce the risk of NCIs in HIV-infectedpatients in general. Further research to investigate NCIs on specific antiretroviral regimens and comorbidities may provide insights regarding the long-term clinical care of these patients.
Authors: Bernadette Jakeman; Alexandra U Scherrer; Katharine E A Darling; Jose Damas; Melanie Bieler-Aeschlimann; Barbara Hasse; Ladina Schlosser; Anna Hachfeld; Klemens Gutbrod; Philip E Tarr; Alexandra Calmy; Frederic Assal; Ursula Kunze; Marcel Stoeckle; Patrick Schmid; Gianina Toller; Stefania Rossi; Caroline di Benedetto; Renaud du Pasquier; Matthias Cavassini; Catia Marzolini Journal: Open Forum Infect Dis Date: 2022-09-02 Impact factor: 4.423
Authors: Maria Martinez de Lagran; Aleix Elizalde-Torrent; Roger Paredes; Bonaventura Clotet; Mara Dierssen Journal: J Cell Mol Med Date: 2022-06-28 Impact factor: 5.295